Current and emerging pharmacotherapeutic strategies for Tourette syndrome

Research output: Contribution to journalArticlepeer-review

71 Downloads (Pure)

Abstract

Introduction

Tourette syndrome (TS) is a chronic tic disorder characterized by both motor and vocal tics. The vast majority of patients present with co-morbid behavioral problems, especially tic-related obsessive-compulsive behaviors and attention-deficit and hyperactivity disorder. Evidence-based guidelines on the pharmacotherapy of TS have become available in recent years.
Areas covered

The main purpose of this paper is to provide an overview of the current and emerging pharmacotherapeutic strategies for TS. A comprehensive search for the literature on the pharmacotherapy of tics was conducted using multiple databases (MEDLINE, Scopus, Web of Science, and Google Scholar), without date limits.
Expert opinion

In consideration of the heterogeneity of the TS phenotypes, pharmacotherapy should be tailored to the individual patient. The choice of the pharmacological agent should take into account both the efficacy-to-tolerability ratio and the presence of co-morbid conditions. Evidence-based pharmacotherapy should aim at improving health-related quality life within a dynamic framework that typically requires active monitoring of the clinical presentation and reevaluation of the treatment intervention over time.
Original languageEnglish
Pages (from-to)1523-1533
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume23
Issue number13
Early online date1 Aug 2022
DOIs
Publication statusE-pub ahead of print - 1 Aug 2022
Externally publishedYes

Keywords

  • Tourette syndrome
  • tics
  • tic disorder
  • pharmacotherapy
  • medications

Fingerprint

Dive into the research topics of 'Current and emerging pharmacotherapeutic strategies for Tourette syndrome'. Together they form a unique fingerprint.

Cite this